Theravance Biopharma Q2 2024 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $14.256M Miss $15.453M Estimate
Portfolio Pulse from Benzinga Newsdesk
Theravance Biopharma (NASDAQ:TBPH) reported Q2 2024 adjusted EPS of $(0.13), beating the analyst estimate of $(0.21) by 38.1%. However, sales of $14.256 million missed the $15.453 million estimate by 7.75%, though they increased by 3.69% year-over-year.
August 05, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Theravance Biopharma's Q2 2024 adjusted EPS of $(0.13) beat estimates by 38.1%, but sales of $14.256 million missed expectations by 7.75%. Sales increased by 3.69% year-over-year.
The mixed results, with EPS beating estimates but sales missing, create a neutral short-term outlook. The EPS beat is positive, but the sales miss and modest year-over-year growth temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100